» Articles » PMID: 24106409

Up-to-seven Criteria for Hepatocellular Carcinoma Liver Transplantation: a Single Center Analysis

Overview
Specialty Gastroenterology
Date 2013 Oct 10
PMID 24106409
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: To detect whether the up-to-seven should be used as inclusion criteria for liver transplantation for hepatocellular carcinoma.

Methods: Between April 2002 and July 2008, 220 hepatocellular carcinoma (HCC) patients who were diagnosed with HCC and underwent liver transplantation (LT) at our liver transplantation center were included. These patients were divided into three groups according to the characteristics of their tumors (tumor diameter, tumor number): the Milan criteria group (Group 1), the in up-to-seven group (Group 2) and the out up-to-seven group (Group 3). Then, we compared long-term survival and tumor recurrence of these three groups.

Results: The baseline characteristics of transplant recipients were comparable among these three groups, except for the type of liver graft (deceased donor liver transplant or live donor liver transplantation). There were also no significant differences in the pre-operative α-fetoprotein level. The 1-, 3-, and 5-year overall survival and tumor-free survival rate for the Milan criteria group were 94.8%, 91.4%, 89.7% and 91.4%, 86.2%, and 86.2% respectively; in the up-to-seven criteria group, these rates were 87.8%, 77.8%, and 76.6% and 85.6%, 75.6%, and 75.6% respectively (P < 0.05). However, the advanced HCC patients' (in the group out of up-to-seven criteria) overall and tumor-free survival rates were much lower, at 75%, 53.3%, and 50% and 65.8%, 42.5%, and 41.7%, respectively (P < 0.01).

Conclusion: Considering that patients in the up-to-seven criteria group exhibited a considerable but lower survival rate compared with the Milan criteria group, the up-to-seven criteria should be used carefully and selectively.

Citing Articles

HepatoPredict Accurately Selects Hepatocellular Carcinoma Patients for Liver Transplantation Regardless of Tumor Heterogeneity.

Andrade R, Perez-Rojas J, da Silva S, Miskinyte M, Quaresma M, Frazao L Cancers (Basel). 2025; 17(3).

PMID: 39941867 PMC: 11816190. DOI: 10.3390/cancers17030500.


APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024.

Lau G, Obi S, Zhou J, Tateishi R, Qin S, Zhao H Hepatol Int. 2024; 18(6):1661-1683.

PMID: 39570557 DOI: 10.1007/s12072-024-10732-z.


Analytical validation and algorithm improvement of HepatoPredict kit to assess hepatocellular carcinoma prognosis before a liver transplantation.

Goncalves-Reis M, Proenca D, Frazao L, Neto J, Silva S, Pinto-Marques H Pract Lab Med. 2024; 39:e00365.

PMID: 38371895 PMC: 10869278. DOI: 10.1016/j.plabm.2024.e00365.


Living-Donor Liver Transplantation for a Large Hepatocellular Carcinoma in a Genetically Identical Twin Sister.

Koek G, Schmitz S, Bednarsch J, Heise D, Longerich T, Bakers F Z Gastroenterol. 2024; 62(1):56-61.

PMID: 38195109 PMC: 10783995. DOI: 10.1055/a-2214-1712.


PIVKA-II combined with tumor burden score to predict long-term outcomes of AFP-negative hepatocellular carcinoma patients after liver resection.

Qiu Z, Wu Y, Qi W, Li C Cancer Med. 2023; 13(1):e6835.

PMID: 38130028 PMC: 10807584. DOI: 10.1002/cam4.6835.


References
1.
Kneteman N, Oberholzer J, Al Saghier M, Meeberg G, Blitz M, Ma M . Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl. 2004; 10(10):1301-11. DOI: 10.1002/lt.20237. View

2.
Suh K, Cho E, Lee H, Shin W, Yi N, Lee K . Liver transplantation for hepatocellular carcinoma in patients who do not meet the Milan criteria. Dig Dis. 2007; 25(4):329-33. DOI: 10.1159/000106913. View

3.
Marsh J, Dvorchik I . Liver organ allocation for hepatocellular carcinoma: are we sure?. Liver Transpl. 2003; 9(7):693-6. DOI: 10.1053/jlts.2003.50086. View

4.
Silva M, Sherman M . Criteria for liver transplantation for HCC: what should the limits be?. J Hepatol. 2011; 55(5):1137-47. DOI: 10.1016/j.jhep.2011.05.012. View

5.
Belghiti J, Durand F . Criteria for liver transplantation for hepatocellular carcinoma: what is an acceptable outcome?. Liver Int. 2011; 31 Suppl 1:161-3. DOI: 10.1111/j.1478-3231.2010.02413.x. View